Quick Takeaways:
- PetIQ has completed the acquisition of MYOS Corp, adding its Fortetropin-based muscle health products, including consumer supplements and veterinary-exclusive formulations. Financial terms were not disclosed.
- MYOS’s portfolio is built around Fortetropin, a patented bioactive compound designed to support muscle growth and preservation by modulating myostatin. The ingredient is backed by 12+ clinical studies, research in dogs, cats, horses and humans, and a robust patent portfolio.
- The acquisition expands PetIQ into the growing muscle health and mobility category, targeting preventive care, recovery and long-term pet vitality. MYOS and Fortetropin will retain their existing brands as PetIQ leverages its retail, e-commerce and distribution network to scale the portfolio.
Why It Matters?
The deal broadens PetIQ’s product mix into a higher-value mobility category that can be cross-sold through retail, e-commerce and distribution channels, potentially increasing average basket size and strengthening PetIQ’s positioning as a branded pet health company rather than just a value pet-products seller. By preserving MYOS and Fortetropin as standalone brands, PetIQ keeps the ingredient’s premium scientific identity intact while gaining leverage to scale consumer supplements and veterinary-exclusive formulations, which could help it compete more effectively in a pet wellness market where owners are willing to pay for products tied to aging, recovery and long-term vitality.
Source: PRnewswire
